More about Ambuja Cements Limited
Fundamentals for Ambuja Cements Limited
Regulatory Filings for Ambuja Cements Limited
Why Oman Is Now India's Most Strategic Trade Partner
Infrastructure Bet Fuels Cement Surge
Apollo FY26: When Healthcare Becomes a Flywheel
NITI Blueprint Could Turn Brain Drain Into $135Bn Engine
Fundamentals for Ambuja Cements Limited
Business Operations:
Sector: Basic MaterialsIndustry: Building Materials
Ambuja Cements Limited, together with its subsidiaries, manufactures and markets cement and cement related products to individual homebuilders, masons and contractors, and architects and engineers in India. The company offers Portland pozzolana cement and ordinary Portland cement, as well as temperature resistant concrete blocks, Blaine Portland cement, and micro materials. It sells its products through dealers, authorized retail stockiest, retailers, and authorized sales representatives. The company was formerly known as Gujarat Ambuja Cements Limited and changed its name to Ambuja Cements Limited in April 2007. The company was incorporated in 1981 and is based in Ahmedabad, India. Ambuja Cements Limited operates as a subsidiary of Holderind Investments Ltd.
Revenue projections:
AMBUJACEM is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.
Financial Ratios:
| currentRatio | 1.04700 |
|---|---|
| forwardPE | 28.24303 |
| debtToEquity | 1.20500 |
| earningsGrowth | 0.74900 |
| revenueGrowth | 0.07200 |
| grossMargins | 0.57021 |
| operatingMargins | 0.06451 |
| trailingEps | 19.05000 |
| forwardEps | 15.55605 |
AMBUJACEM's current ratio being 1.047 shows it has more than enough assets to cover its short-term debts. The company's liquidity position is strong, with ample cash reserves available to meet its immediate financial obligations without strain.
AMBUJACEM's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.
AMBUJACEM's forward EPS is lower than its trailing EPS, signaling that the company is projected to experience reduced profitability this year. This suggests a downward trend in earnings, which could raise concerns among investors about AMBUJACEM's financial outlook.
Price projections:
AMBUJACEM's price projections have been revised downward over time, reflecting a shift in sentiment among analysts. The steady decline in projections points to a more cautious outlook on the company's future performance.
Recommendation changes over time:
Analysts are favoring AMBUJACEM with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider AMBUJACEM as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
RAINMUMBAI Turns Rain Into a Financial Asset
India’s IT Sector Faces a Historic Breaking Point
How Independent Directors Failed Rs 2,500 Crore in Value